Table 4.
Pharmacologic Treatments Approved by the FDA24
| Drug | FDA Approval | What is it? |
|---|---|---|
| Tegaserod | 2002 (reintroduced in 2019 and withdrawn from the market by manufacturer in 2022) | Serotonin (5-HT4) receptor agonist |
| Lubiprostone | 2006 | Chloride channel type II agonist |
| Linaclotide | 2012 | GC-C agonists |
| Plecanatide | 2017 | |
| Tenapanor | 2019 (initial FDA approval) 2022 (US launch) | NHE3 inhibitor |
FDA, US Food and Drug Administration; GC-C, guanylate cyclase-C; NHE3, sodium/hydrogen exchange transporter isoform 3.